Medivation Reports First Quarter Financial Results and Provides Corporate Update - MarketWatch (press release)
Medivation Reports First Quarter Financial Results and Provides Corporate UpdateMarketWatch (press release)Continued to enroll patients in the Phase 2 TERRAIN trial, which is comparing the effect of enzalutamide versus bicalutamide, the most commonly used anti-androgen, on progression-free survival in approximately 370 men with advanced prostate cancer who .
MDVN Misses; Focus on Enzalutamide - Zacks.com
MDVN Misses; Focus on EnzalutamideZacks.
MDVN Misses; Focus on Enzalutamide - Analyst Blog - NASDAQ
MDVN Misses; Focus on Enzalutamide - Analyst BlogNASDAQEnzalutamide is also in a phase II study (TERRAIN), which will compare enzalutamide with bicalutamide, in advanced prostate cancer patients who have progressed following medical castration with LHRH analog therapy or surgical castration.
New Therapies for Prostate Cancer: The Practicalities - OncLive
OncLiveNew Therapies for Prostate Cancer: The PracticalitiesOncLive12,13 This investigational agent is an irreversible androgen receptor (AR) antagonist and AR signaling inhibitor, and represents an advance from the nonsteroidal AR antagonists flutamide, bicalutamide, and nilutamide.